AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32600320
Drug: Lactose challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose challenge (50 g lactose)
Trial: 32600320
Drug: Conventional milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional milk (750 mL, 37.5 g lactose)
Trial: 32600320
Drug: A1 β-casein-free
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1 β-casein-free milk (a2 Milk™) (750 mL, 37.5 g lactose)
Trial: 33422174
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy 20 mg once a week
Trial: 33422174
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg daily with topical minoxidil
Trial: 33866774
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor (gemigliptin)
Trial: 33866774
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor (sitagliptin)
Trial: 34410358
Drug: Cipargamin (KAE609)
RxNorm normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin (KAE609) single doses of 50 to 150 mg
Trial: 33522951
Drug: Homeopathy: 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30%, taken orally every 4 hours while symptomatic, then every 6 hours until the fourteenth day.
Trial: 33522951
Drug: Placebo: 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle, taken orally every 4 hours while symptomatic, then every 6 hours until the fourteenth day.
Trial: 32515740
Drug: Coach-guided web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coach-guided web-based therapy (The Journal) for 12 weeks
Trial: 36805437
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist trigger
Trial: 34130573
Drug: Proactive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive management with Cal/BD foam (twice-weekly application)
Trial: 34130573
Drug: Reactive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive management with Cal/BD foam (once-daily for four weeks after relapse)
Trial: 33548084
Drug: Quadruple single-pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple single-pill combination (reserpine 0.1 mg, dihydralazine 12.5 mg, hydrochlorothiazide 12.5 mg, triamterene 12.5 mg)
Trial: 33548084
Drug: Quadruple single-pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple single-pill combination
Trial: 34677005
Drug: Hypochlorite-based formula
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypochlorite-based formula brushing solution
Trial: 32969733
Drug: Hydromorphone 1
RxNorm normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 1 mg/kg
Trial: 32969733
Drug: Hydromorphone 2
RxNorm normalized name: HYDROmorphone 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 2 mg/kg
Trial: 32969733
Drug: Hydromorphone 1
RxNorm normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 1 mg/kg and 2 mg/kg
Trial: 33516795
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy (NPWT)
Trial: 34741103
Drug: Rotarix (live‐attenuated,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix (live‐attenuated, oral rotavirus vaccine)
Trial: 32609331
Drug: Icosapent Ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent Ethyl (IPE) 4 g/day
Trial: 35064942
Drug: Ethanol (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (approximately 0.7 ml/kg)
Trial: 34620496
Drug: Ceralasertib 160
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib 160 mg orally daily (days 1-7) and olaparib 300 mg orally twice daily (days 1-28) of a 28-day cycle until toxicity or progression
Trial: 35462033
Drug: Guideline-Directed Medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-Directed Medical Therapy (GDMT)
Trial: 35462033
Drug: Angiotensin-converting enzymes/angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzymes/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors
Trial: 35048423
Drug: AZ-009 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZ-009 (2 mg)
Trial: 35048423
Drug: AZ-009 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZ-009 (3 mg)
Trial: 35048423
Drug: AZ-009 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZ-009 (4 mg)
Trial: 33268527
Drug: Active conventional
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active conventional treatment (either prednisolone tapered to 5 mg/day, or sulfasalazine combined with hydroxychloroquine and intra‐articular corticosteroids)
Trial: 35810757
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy (intravenous thrombolytic before endovascular thrombectomy)
Trial: 34727741
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy
Trial: 34155159
Drug: Intravenous Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Dexmedetomidine (DEX) administered at an initial dose of 1 µg/kg over 10 minutes, followed by a continuous infusion at 0.4 μg/kg/h until 30 minutes before the end of surgery.
Trial: 34155159
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral superficial cervical plexus block (SCPB) with 10 mL of 0.375% ropivacaine injected on each side.
Trial: 34155159
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline administered at the same rate and dose as in group D.
Trial: 35139044
Drug: Intrathecal chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal chloroprocaine 49.5 mg with fentanyl 10 ug
Trial: 36188435
Drug: RQ3013 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RQ3013 (30 μg mRNA per 0.15 mL)
Trial: 36188435
Drug: ChAdTS-S (5×10^10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdTS-S (5×10^10 viral particles per 0.5 mL)
Trial: 36188435
Drug: ZR202-CoV (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZR202-CoV (25 μg per 0.5 mL)
Trial: 36188435
Drug: CoronaVac (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (3 μg inactivated CN02 strain of SARS-CoV-2 per 0.5 mL)
Trial: 36188435
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mL of 0.9% sodium chloride solution)
Trial: 35633654
Drug: Inulin+Traditional Chinese
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin+Traditional Chinese Medicine (TCM)
Trial: 35633654
Drug: Inulin+Metformin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin+Metformin
Trial: 32789480
Drug: PCb (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCb (paclitaxel 80 mg/m2 and carboplatin [AUC = 2] on days 1, 8, and 15 every 28 days for 6 cycles)
Trial: 32789480
Drug: CEF-T (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF-T (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, and fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles)
Trial: 35869929
Drug: HDIT101 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDIT101 (doses up to 12,150 mg)
Trial: 35967104
Drug: Atacicept 25
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept 25 mg
Trial: 33503610
Drug: One Strength
RxNorm normalized name: Voltaren Joint Health And Bone Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Strength Group (3 injections with 1 strength B, 10,000 TU/mL)
Trial: 33503610
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (7 injections with 2 strengths A (1,000 TU/mL) and B (10,000 TU/mL))
Trial: 33070326
Drug: Water as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water as a neutralising agent
Trial: 33070326
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate plus solution (Control)
Trial: 36335517
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg/d)
Trial: 34515079
Drug: Osteopathic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic medicine (OM) sessions (up to six sessions) in addition to routine care
Trial: 35638455
Drug: 3% NaCl
RxNorm normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% NaCl solution
Trial: 36077145
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (200 µg or 8000 IU)
Trial: 33407848
Drug: Tailored Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored Intervention (TI) including one face-to-face counseling session incorporating cognitive behavioral therapy and 30 days of 2-way text messaging
Trial: 34158786
Drug: Non-adherence to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherence to antihypertensive medications (AHTNM)
Trial: 34158786
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of antihypertensive medications (AHTNM)
Trial: 32265309
Drug: Inhaled Aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Aztreonam
Trial: 34315508
Drug: Proprioceptive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioceptive training with Flexibar® (9 min daily for 12 weeks)
Trial: 34315508
Drug: Proprioceptive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioceptive training with Flexibar® (9 min daily for 12 weeks) and at least 40 min running or walking/week with XCO®
Trial: 35213109
Drug: Low‐Level Light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐Level Light Amplification by Stimulated Emission of Radiation therapy (LLLT) using Diode LASER
Trial: 35213109
Drug: Topical Anginovag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Anginovag spray medication
Trial: 35213109
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with motivation and follow‐up
Trial: 34792562
Drug: TTV cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTV cut-off level of 1.2 × 10^6 c/ml at month 3
Trial: 32212089
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus Metformin (arm A)
Trial: 32402609
Drug: Remotely supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely supervised cranial electrical stimulation (CES) for 10 daily sessions (60 min each) over two weeks
Trial: 35719338
Drug: High-dose VA
RxNorm normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose VA therapy (amoxicillin 1 g t.i.d. and VPZ 20 mg b.i.d.)
Trial: 35719338
Drug: Low-dose VA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose VA therapy (amoxicillin 1 g b.i.d. and VPZ 20 mg b.i.d.)
Trial: 33320103
Drug: Dance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance and yoga intervention (twice weekly for 8 months)
Trial: 32179906
Drug: Multimatrix mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimatrix mesalazine (combined dose groups, 2.4 or 4.8 g/day)
Trial: 34886746
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (60 mL, placebo)
Trial: 36412382
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (HTV) ventilation, 12-15 mL/kg (group H)
Trial: 36412382
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (LTV) ventilation, 6-8 mL/kg (group L)
Trial: 32063059
Drug: Aprocitentan 10
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 10 mg
Trial: 32063059
Drug: Aprocitentan 25
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 25 mg
Trial: 32063059
Drug: Aprocitentan 50
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 50 mg
Trial: 32063059
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg (positive control)
Trial: 34491022
Drug: aboBoNT‐A 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aboBoNT‐A 50 U (5 injections of 0.1 mL each)
Trial: 32267205
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose regimen (TDF 200 mg, efavirenz 400 mg, lamivudine 300 mg)
Trial: 32267205
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose regimen
Trial: 32267205
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose regimen and Standard dose regimen
Trial: 32348700
Drug: Combined screening
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined screening and treatment program targeting psychological distress
Trial: 35197490
Drug: Transcranial Magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Magnetic Stimulation (TMS) sessions daily over five consecutive days
Trial: 36107715
Drug: Dopamine D2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2/3 receptor availability (BPND) in people who smoke
Trial: 33686407
Drug: Standard 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 150 IU dose proposed by the OPTIMIST trial
Trial: 33686407
Drug: Starting dose
RxNorm normalized name: Austedo 6 MG Starting Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose >300 IU
Trial: 35477876
Drug: App conditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App conditional feedback group (250 patients) using the medication reminder app for medication and BP check alarms.
Trial: 35477876
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (250 patients).
Trial: 33337995
Drug: Anti-citrullinated peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-citrullinated peptide antibodies (ACPA) positive subjects
Trial: 33399175
Drug: Maitland therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maitland therapy (central or unilateral postero‐anterior pressure) for 2 sessions/week for 3 weeks
Trial: 34059737
Drug: Program B
RxNorm normalized name: ZINC OXIDE 3 g in 100 g / OCTOCRYLENE 6 g in 100 g / ENSULIZOLE 4 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g TOPICAL CREAM [NECK DECOLLETE HAND ARM DAY REPARATIVE HYDRATION RESCUE AND REPROGRAM BROAD SPECTRUM SPF 35 SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program B (fixed-order, internet cognitive behavioral therapy, iCBT)
Trial: 32918160
Drug: Commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial formulation
Trial: 35361325
Drug: Cream-based formulation
RxNorm normalized name: phenylephrine hydrochloride / shark liver oil Rectal Cream [Formulation R]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream-based formulation
Trial: 35361325
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment area
Trial: 35118971
Drug: Tablet-based interactive
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based interactive distraction
Trial: 33813580
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: 35686900
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% permethrin and oral placebo (Group A)
Trial: 35686900
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo cream and oral ivermectin (Group B)
Trial: 35686900
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% gamma benzene hexachloride and oral placebo (Group C)
Trial: 35686900
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% permethrin and oral ivermectin (Group D)
Trial: 32392715
Drug: Intensive Lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Lifestyle Treatment (ILT) - diet plus exercise with monthly visits
Trial: 38743692
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated vaccine (TIV)
Trial: 35689818
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L polyethylene glycol and ascorbate (PEG/Asc)
Trial: 32737604
Drug: Dose-Response Mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Response Mixed Models for Repeated Measures (DR-MMRM)
Trial: 32737604
Drug: Dose-response model
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response model
Trial: 35021015
Drug: Linguistic-phonological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linguistic-phonological intervention to eliminate anterior oral CSCs
Trial: 35021015
Drug: Motor-phonetic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor-phonetic intervention to eliminate anterior oral CSCs
Trial: 35021015
Drug: Motor-phonetic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor-phonetic intervention to eliminate non-oral CSCs
Trial: 35021015
Drug: Linguistic-phonological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linguistic-phonological intervention to eliminate non-oral CSCs
Trial: 36302173
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg)
Trial: 32517192
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide)
Trial: 33184437
Drug: Dietary probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary probiotic supplement of four viable strains of Lactobacillus twice-daily for 14 days
Trial: 35407595
Drug: Negative pulsed-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pulsed-pressure myofascial vacuum therapy (VT)
Trial: 35407595
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy program (PTP) based only on core therapeutic exercise
Trial: 32763548
Drug: Quetiapine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (100 mg)
Trial: 34150674
Drug: Oral liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liposomal glutathione supplementation (L-GSH) for 3 months
Trial: 38498141
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg
Trial: 35833298
Drug: 7+3 induction
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7+3 induction chemotherapy
Trial: 39575611
Drug: Clonidine therapy
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine therapy
Trial: 34228086
Drug: Antibiotic initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibiotic initiation letter (n = 1500)